Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 07 Dec 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jan 2019.
- 13 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Oct 2018.
- 23 Apr 2018 New trial record